NDAORALTABLET, EXTENDED RELEASE
Approved
Feb 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
17
Data completeness
4/8 — Partial
SULAR (nisoldipine) by R-Pharm US is calcium channel antagonists [moa]. First approved in 1995.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SULAR (nisoldipine) is an oral extended-release dihydropyridine calcium channel blocker approved in 1995 for hypertension management. It works by antagonizing calcium channels to reduce vascular smooth muscle contraction and lower blood pressure. The drug is indicated for patients requiring once-daily antihypertensive therapy.
$0.352MPart D
LOE ApproachingMature product with minimal Part D penetration ($352K annual spending, 159 claims in 2023) signals a legacy brand nearing loss of exclusivity with constrained team expansion.
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (17)
Comparison of the Analgesic Efficacy and Duration of Analgesic Effect of Pericapsular Nerve Group Block Block Application With PENG Block and Pulse Radiofrequency Ablation in Chronic Hip Pain
Started Jan 2025
40 enrolled
Hip Pain Chronic
Knotless Implants As an Alternative for Capsular Closure in Primary Hip Arthroscopy: a Prospective, Multi-Center Study
Started Oct 2024
80 enrolled
Femoro Acetabular Impingement
Microinterventional Endocapsular Nuclear Fragmentation Assisted Cataract Surgery
Started Apr 2023
80 enrolled
Nuclear Cataract
Fixation Versus Arthroplasty for Undisplaced Intracapsular Fractures
Started May 2016
50 enrolled
Hip FracturesUndisplaced Intracapsular Hip Fracture
Insular Inhibitory Neuromodulation to Reduce Cigarette Craving and Alter Brain Function in Smokers
Started Nov 2015
40 enrolled
Smoking
Worked on SULAR at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.